For Healthcare Professionals Outside the US

For patients with BRAF V600 mutation–positive unresectable or metastatic melanoma

For patients with BRAF V600 mutation–positive advanced non-small cell lung cancer (NSCLC)

Patients with BRAF V600+ NSCLC may have an aggressive disease

  • BRAF V600+ NSCLC has histological features suggestive of an aggressive tumor1
  • BRAF mutations may be linked to shorter disease-free survival and overall survival compared with patients with wild-type BRAF1

Overall survival based on presence or absence of BRAF V600 mutation1

Chart of overall survival based on presence or absence of BRAF V600 mutation.

Tafinlar + Mekinist is the first and only approved targeted treatment for patients with BRAF V600+ NSCLC2

A retrospective study to investigate the prevalence, distribution, and prognostic role of BRAF mutations in a large cohort of Caucasian patients with NSCLC (N=1046).1

References: 1. Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non–small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011;29(26):3574-3579.
2. Tafinlar Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2017.